NASD · Healthcare · Biotechnology · Denmark
Ascendis Pharma A/S is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Ascendis Pharma A/S stock.
Overvalued: intrinsic value $86.66 per share, market price $271.19, margin of safety -213.0% (as of 2026-11-17).
A 4.2x revenue multiple, discounted for its losses, values the shares at $86.66; the price of $271.19 is 213% above that value.
17 more funds hold it; the full list is part of the paid plan.
70 more in this industry show a wider margin of safety.
ASND is overvalued (as of the 2026-11-17 close). A 4.2x revenue multiple, discounted for its losses, values the shares at $86.66; the price of $271.19 is 213% above that value.
$86.66 per share (as of the 2026-11-17 close), against a market price of $271.19. That is a margin of safety of -213.0%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.